LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3
2024; Elsevier BV; Volume: 35; Linguagem: Inglês
10.1016/j.annonc.2024.08.2307
ISSN1569-8041
AutoresSilke Gillessen, Ananya Choudhury, F. Saad, E. Gallardo, André Soares, Y. Loriot, Ray McDermott, Alejo Rodríguez‐Vida, P G Isaacson, Franco Nolè, F.J.S. Melo Cruz, T. Roumeguere, Kirsten Gedske Daugaard, Rosely Yamamura, F. Lecouvet, Corneel Coens, B. Fournier, Bertrand Tombal,
Tópico(s)Medical Imaging Techniques and Applications
Referência(s)